These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1810192)

  • 1. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex.
    Hodges TL; Kahn JO; Kaplan LD; Groopman JE; Volberding PA; Amman AJ; Arri CJ; Bouvier LM; Mordenti J; Izu AE
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2580-6. PubMed ID: 1810192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
    Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex.
    Collier AC; Coombs RW; Katzenstein D; Holodniy M; Gibson J; Mordenti J; Izu AE; Duliege AM; Ammann AJ; Merigan T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):150-6. PubMed ID: 7552478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146.
    Shearer WT; Duliege AM; Kline MW; Hammill H; Minkoff H; Ammann AJ; Chen S; Izu A; Mordenti J
    Clin Diagn Lab Immunol; 1995 May; 2(3):281-5. PubMed ID: 7664172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recombinant CD4-IgG in the treatment of AIDS and correlated syndromes: 1st stage of the study].
    Di Nola F
    Minerva Pediatr; 1992; 44(7-8):385. PubMed ID: 1406513
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.
    Kahn JO; Kaplan LD; Gambertoglio JG; Bredesen D; Arri CJ; Turin L; Kibort T; Williams RL; Lifson JD; Volberding PA
    AIDS; 1990 Dec; 4(12):1197-204. PubMed ID: 2088398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex.
    Levine JD; Allan JD; Tessitore JH; Falcone N; Galasso F; Israel RJ; Groopman JE
    Blood; 1991 Dec; 78(12):3148-54. PubMed ID: 1742482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.
    Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex.
    Kahn JO; Gorelick KJ; Gatti G; Arri CJ; Lifson JD; Gambertoglio JG; Bostrom A; Williams R
    Antimicrob Agents Chemother; 1994 Feb; 38(2):260-7. PubMed ID: 7910722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS.
    Clerici M; Yarchoan R; Blatt S; Hendrix CW; Ammann AJ; Broder S; Shearer GM
    J Infect Dis; 1993 Oct; 168(4):1012-6. PubMed ID: 8376811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.
    Yarchoan R; Mitsuya H; Thomas RV; Pluda JM; Hartman NR; Perno CF; Marczyk KS; Allain JP; Johns DG; Broder S
    Science; 1989 Jul; 245(4916):412-5. PubMed ID: 2502840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
    Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
    Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.
    Liebman HA; Cooley TP
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S52-8. PubMed ID: 8093847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.